Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6

International Journal of Cancer

Volumn 136, Issue 1, 2015, Pages 65-73

  Bhattacharya, Nupur ^a   Reichenzeller, Michaela ^a   Caudron Herger, Maiwen ^b   Haebe, Sarah ^a   Brady, Nathan ^c,d   Diener, Susanne ^a   Nothing, Maria ^a   Döhner, Hartmut ^a   Stilgenbauer, Stephan ^a   Rippe, Karsten ^d   Mertens, Daniel ^a,e  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; chronic lymphocytic leukemia; IL4; NF kB; sCD40L

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; CD40 LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; STAT6 PROTEIN; STROMAL CELL DERIVED FACTOR 1; IL4 PROTEIN, HUMAN; STAT6 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; LEUKEMIA CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; TRANSCRIPTION INITIATION; TUMOR MICROENVIRONMENT; CASE CONTROL STUDY; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; SECRETION (PROCESS); SIGNAL TRANSDUCTION;

APOPTOSIS; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CD40 LIGAND; CELL SURVIVAL; HUMANS; INTERLEUKIN-4; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NF-KAPPA B; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR;

EID: 84925285029     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28974     Document Type: Article

References (51)

1. Zenz T, Mertens D, Küppers R, et al., From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37-50.
2. Seiffert M, Stilgenbauer S, Döhner H, et al., Efficient nucleofection of primary human B-cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids. Leukemia 2007; 21: 1977-83.
3. Ramsay AG, Johnson AJ, Lee AM, et al., Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008; 118: 2427-37.
4. Bhattacharya N, Diener S, Idler IS, et al., Non-malignant B cells and chronic lymphocytic leukemia cells induce a prosurvival phenotype in CD14+ cells from peripheral blood. Leukemia 2011; 25: 722-6.
5. Seiffert M, Schulz A, Ohl S, et al., Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro, and present at abnormally high levels in vivo. Blood 2010; 116: 4223-30.
6. Ramsay AG, Johnson AJ, Lee AM, et al., Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008; 118: 2427-37.
7. Burger JA, Tsukada N, Burger M, et al., Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000; 15: 2655-63.
8. Lagneaux L, Delforge A, Bron D, et al., Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998; 91: 2387-96.
9. Burger JA, Kipps TJ,. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107: 1761-7.
10. Bürkle A, Niedermeier M, Schmitt-Gräff A, et al., Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 2007; 110: 3316-25.
11. Nishio M, Endo T, Tsukada N, et al., Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005; 106: 1012-20.
12. Han T, Barcos M, Emrich L, et al., Bone marrow infiltration patterns and their prognostic significance in chronic lymphocytic leukemia: correlations with clinical, immunologic, phenotypic, and cytogenetic data. J Clin Oncol 1984; 2: 562-70.
13. Chiorazzi N, Rai KR, Ferrarini M,. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-15.
14. Pizzolo G, Chilosi M, Ambrosetti A, et al., Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia. Blood 1983; 62: 1289-96.
15. Stevenson FK, Caligaris-Cappio F,. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004; 103: 4389-95.
16. Granziero L, Ghia P, Circosta P, et al., Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2777-83.
17. Coscia M, Pantaleoni F, Riganti C, et al., IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia 2011; 25: 828-37.
18. Schattner EJ, Mascarenhas J, Reyfman I, et al., Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity. Blood 1998; 91: 2689-97.
19. George TC, Basiji DA, Hall BE, et al., Distinguishing modes of cell death using the ImageStream multispectral imaging flow cytometer. Cytometry A 2004; 59: 237-45.
20. Caudron-Herger M, Muller-Ott K, Mallm JP, et al., Coding RNAs with a non-coding function: maintenance of open chromatin structure. Nucleus 2011; 2: 410-24.
21. Douglas RS, Capocasale RJ, Lamb RJ, et al., Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta. Blood 1997; 89: 941-7.
22. Bodmer JL, Schneider P, Tschopp J,. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002; 27: 19-26.
23. Lane P, Brocker T, Hubele S, et al., Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation. J Exp Med 1993; 177: 1209-13.
24. Wieckowski S, Trouche N, Chaloin O, et al., Cooperativity in the interaction of synthetic CD40L mimetics with CD40 and its implication in cell signaling. Biochemistry 2007; 46: 3482-93.
25. Hebenstreit D, Wirnsberger G, Horejs-Hoeck J, et al., Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev 2006; 17: 173-88.
26. Kaplan MH, Schindler U, Smiley ST, et al., Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996; 4: 313-9.
27. Kay NE, Pittner BT,. IL-4 biology: impact on normal and leukemic CLL B cells. Leuk Lymphoma 2003; 44: 897-903.
28. Damle RN, Wasil T, Fais F, et al., Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-7.
29. Steele AJ, Prentice AG, Cwynarski K, et al., The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment. Blood 2010; 116: 4569-77.
30. Spriggs MK, Armitage RJ, Strockbine L, et al., Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med 1992; 176: 1543-50.
31. Elgueta R, Benson MJ, de Vries VC, et al., Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009; 229: 152-72.
32. Snapper CM, Zelazowski P, Rosas FR, et al., B cells from p50/NF-kappa B knockout mice have selective defects in proliferation, differentiation, germ-line CH transcription, and Ig class switching. J Immunol 1996; 156: 183-91.
33. Jacob A, Pound JD, Challa A, et al., Release of clonal block in B cell chronic lymphocytic leukaemia by engagement of co-operative epitopes on CD40. Leuk Res 1998; 22: 379-82.
34. Munk Pedersen I, Reed J,. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 2004; 45: 2365-72.
35. Dancescu M, Rubio-Trujillo M, Biron G, et al., Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992; 176: 1319-26.
36. Wurster AL, Rodgers VL, White MF, et al., Interleukin-4-mediated protection of primary B cells from apoptosis through Stat6-dependent up-regulation of Bcl-xL. J Biol Chem 2002; 277: 27169-75.
37. Nelms K, Keegan AD, Zamorano J, et al., The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999; 17: 701-38.
38. Fluckiger AC, Rossi JF, Bussel A, et al., Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood 1992; 80: 3173-81.
39. Furman RR, Asgary Z, Mascarenhas JO, et al., Modulation of NF-{kappa}B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000; 164: 2200-6.
40. Lapalombella R, Andritsos L, Liu Q, et al., Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 2010; 115: 2619-29.
41. Mazzei GJ, Edgerton MD, Losberger C, et al., Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem 1995; 270: 7025-8.
42. Berberich I, Shu GL, Clark EA,. Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B. J Immunol 1994; 153: 4357-66.
43. Caligaris-Cappio F, Ghia P,. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 2008; 26: 4497-503.
44. Gorgun G, Ramsay AG, Holderried TA, et al., E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA 2009; 106: 6250-5.
45. Chiorazzi N,. Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol 2007; 20: 399-413.
46. Ghia P, Circosta P, Scielzo C, et al., Differential effects on CLL cell survival exerted by different microenvironmental elements. Curr Top Microbiol Immunol 2005; 294: 135-45.
47. Scielzo C, Apollonio B, Scarfo L, et al., The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. Leukemia 2011; 25: 1760-7.
48. Hewamana S, Alghazal S, Lin TT, et al., The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008; 111: 4681-9.
49. Escobar-Diaz E, Lopez-Martin EM, Hernandez del Cerro M, et al., AT514, a cyclic depsipeptide from Serratia marcescens, induces apoptosis of B-chronic lymphocytic leukemia cells: interference with the Akt/NF-kappaB survival pathway. Leukemia 2005; 19: 572-9.
50. Pickering BM, de Mel S, Lee M, et al., Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 2007; 26: 1166-77.
51. Steele AJ, Jones DT, Ganeshaguru K, et al., The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro. Leukemia 2006; 20: 1073-9.